Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.87, denoting a -1.53% change from the preceding trading day.

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90 ...

To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

The Vietnam Hepatitis Treatment Market was valued at USD 146.25 million in 2023 and is projected to reach USD 197.35 million by 2029, growing at a CAGR of 5.08% during the forecast period. The ...

Hepatitis C Diagnosis and Treatment The hepatitis c diagnosis and treatment market size are predicted to develop because of the factors suc ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but ...

The company is best known for its HIV and hepatitis C therapies, including Biktarvy ... Looking ahead, for 2025, Gilead projects product sales between $28.2 billion and $28.6 billion, and expects ...